Insights From the Experts at Teiko
Learn about the latest advances in immune profiling from Teiko’s team of scientific experts.
CLIA Validation Data for Teiko Bio’s PBMC Immune Profiling Assay
In this live webinar, Ramji Srinivasan, cofounder and CEO of Teiko Bio, will walk through the precision and stability data for our mass cytometry assay for pan-immune profiling of PBMCs isolated from healthy human clinical samples.
Discovery of immune-related adverse event associations in metastatic melanoma
Ramji Srinivasan, cofounder and CEO of Teiko Bio, shares original research on blood-based biomarkers of immune-related adverse events in metastatic melanoma performed by Teiko scientists in collaboration with Dr. Siwen Hu-Lieskovan of Huntsman Cancer Institute.
Understanding the immune setpoint – a new approach to cancer treatment
Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy.
Whole Blood or PBMCs for immune profiling?
Dr. Jolien Sweere discusses data from a technical validation experiment performed by Teiko Bio showing how mass cytometry immune profiling data from whole blood compares to data from PBMCs.
What looking beyond the tumor microenvironment has taught us about immunotherapy
Dr. Jolien Sweere walks us through scientific publications showing that immune responses outside the tumor are necessary for effective immunotherapy.
Accelerating therapeutic discovery in blood cancer
We highlight six recent key discoveries made using mass cytometry across a wide range of blood cancers including AML ALL, lymphoma, and myeloma.
Immune responses to cancer immunotherapy outside the tumor
Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar.
What the Costco hot dog teaches us about our immune system
What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system.
Customer Spotlight: Shernan Holtan, MD
Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling.
Two peas in a pod: The complementary capabilities of single-cell RNA seq and mass cytometry
Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings.
Peripheral blood analysis is key to developing effective cancer immunotherapies
Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline.
Flow vs. Spectral vs. Mass Cytometry: What’s the difference?
What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development.
Five things to look for in an immune profiling partner
Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner.